Atelerix Life Sciences

Atelerix Life Sciences Appoints James Bates as CMO

CHARLOTTESVILLE, VA, UNITED STATES, September 14, 2021 / — Atelerix Life Sciences Inc., a leader in new therapeutics for unmet medical needs related to opioid use, today announced the appointment of James Bates, MD, PhD, to the position of Chief Medical Officer, where he will oversee the Company’s drug development initiatives. Dr. Bates comes to Atelerix from the University of Iowa, where, in addition to engaging in multiple NIH-sponsored drug discovery and development programs, he was a full-time clinical anesthesiologist for 35 years. Dr. Bates is a co-inventor of Atelerix’s platform of novel Active Thiol-Based Compounds (ATBCs), including its lead drug Atlex-1099 (also called Sudaxine.)